Laser assisted thrombolysis
The present disclosure relates to methods and systems for removing a vascular obstruction in a subject using a combination of thrombolytic and laser ablation therapy. Treatment methods include positioning a catheter adjacent to an obstruction within a vessel of a subject. A portion of the obstruction may be ablated by delivering laser energy through the optical fibers to the distal end of the catheter, where the optical fibers are exposed, and circulating a fluid containing one or more thrombolytic agents to a remaining portion of the obstruction for a predetermined amount time. Fluid containing one or more thrombolytic agents capable of dissolving a remaining portion of the obstruction may be circulated through the fluid delivery lumen and removed through the fluid removal lumen.
1. A method of treating thrombosis in a subject, the method comprising:
positioning a catheter within a vessel of a subject, wherein the catheter comprises a proximal end, a distal end, a plurality of optical fibers, a fluid delivery lumen and a fluid removal lumen, at least one fluid delivery port coupled to the fluid delivery lumen and disposed adjacent and exteriorly the distal end, and at least one fluid removal port coupled to the fluid removal lumen and disposed adjacent and exteriorly the distal end, wherein the distal end comprises a distal face, wherein the plurality of optical fibers extend through at least a portion of the catheter to the distal face, wherein the plurality of optical fibers are exposed at the distal face, and wherein the distal end of the catheter is positioned adjacent an obstruction in the vessel;
ablating at least a portion of the obstruction by delivering laser energy through the plurality of optical fibers to the distal face of the catheter for between 2 minutes and 10 minutes;
circulating a fluid to a remaining portion of the obstruction for between 20 minutes and 40 minutes, wherein the fluid circulates through the fluid delivery lumen, exits the fluid delivery port, and returns through the fluid removal port to the fluid removal lumen, the fluid comprising one or more thrombolytic agents.
2. The method of claim 1 , wherein ablating at least a portion of the obstruction occurs prior to circulating the fluid.
3. The method of claim 1 , wherein ablating at least a portion of the obstruction occurs simultaneously with circulating the fluid.
4. The method of claim 1 , wherein the ablation procedure occurs for about 5 minutes.
5. The method of claim 1 , wherein the fluid is in contact with the remaining portion of the obstruction for about 30 minutes.
6. The method of claim 1 , wherein the one or more thrombolytic agents includes tissue plasminogen activator, heparin, urokinase, streptokinase, kabikinase, anistreplase, reteplase, tenecteplase and rokinase.
7. The method of claim 1 , wherein the one or more thrombolytic agents is tissue plasminogen activator administered to the subject at a dosage between about 0.5 and about 1.2 milligrams per kilogram of the subject's body weight.
8. The method of claim 1 , wherein the one or more thrombolytic agents is tissue plasminogen activator administered to the subject at a dosage of about 0.9 milligrams per kilogram of the subject's body weight.
9. A system for treating thrombosis in a subject, the system comprising:
a laser ablation catheter comprising:
a proximal end,
a distal end,
a sidewall extending between the proximal end and the distal end,
a guidewire lumen disposed within the sidewall and extending between the proximal end and the distal end,
a fluid delivery lumen disposed within the sidewall,
at least one fluid delivery port coupled to the fluid delivery lumen and disposed on the sidewall proximal to the distal end,
a fluid removal lumen disposed within the sidewall,
at least one fluid removal port coupled to the fluid removal lumen and disposed on the sidewall proximal to the distal end,
a plurality of optical fibers, wherein the distal end comprises a distal face, wherein the plurality of optical fibers extend through at least a portion of the catheter to the distal face, and wherein the plurality of optical fibers are exposed at the distal face of the catheter;
wherein the distal end of the catheter is positioned adjacent to an obstruction in a vessel of a subject to facilitate ablation of at least a portion of the obstruction by delivering laser energy through the plurality of optical fibers to the distal face; and
wherein a fluid comprising one or more thrombolytic agents circulates through the fluid delivery lumen, exits the fluid delivery port, and returns through the fluid removal port to the fluid removal lumen such that it contacts a remaining portion of the obstruction for a predetermined amount of time.
10. The system of claim 9 , wherein ablating at least a portion of the obstruction occurs prior to circulating the fluid.
11. The system of claim 9 , wherein ablating at least a portion of the obstruction occurs simultaneously with circulating the fluid.
12. The system of claim 9 , wherein the ablation procedure occurs for between about 2 minutes and about 10 minutes.
13. The system of claim 9 , wherein the ablation procedure occurs for about 5 minutes.
14. The system of claim 9 , wherein the fluid is in contact with the remaining portion of the obstruction for between about 10 minutes and about 60 minutes.
15. The system of claim 9 , wherein the fluid is in contact with the remaining portion of the obstruction for about 30 minutes.
16. The system of claim 9 , wherein the one or more thrombolytic agents includes tissue plasminogen activator (tPA), heparin, alteplase, anistreplase, kabikinase, prourokinase, reteplase, rokinase, streptokinase, tenecteplase and urokinase.
17. The system of claim 9 , wherein the one or more thrombolytic agents is tissue plasminogen activator administered to the subject at a dosage between about 0.5 and about 1.2 milligrams per kilogram of the subject's body weight.
18. The system of claim 9 , wherein the one or more thrombolytic agents is tissue plasminogen activator administered to the subject at a dosage of about 0.9 milligrams per kilogram of the subject's body weight.